Neurocognitive function after WBRT plus SRS or SRS alone

The Lancet Oncology

Volumn 11, Issue 3, 2010, Pages 220-221

  Weiss, Stephanie E ^a,b   Kelly, Paul J ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

BRAIN METASTASIS; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; COGNITION; CRANIOTOMY; HUMAN; LETTER; PRIORITY JOURNAL; PROGNOSIS; RECALL; RISK BENEFIT ANALYSIS; SALVAGE THERAPY; STEREOTACTIC RADIOSURGERY; VISCERAL METASTASIS; WHOLE BRAIN RADIOTHERAPY;

BRAIN NEOPLASMS; COGNITION DISORDERS; CRANIAL IRRADIATION; HUMANS; RADIOSURGERY; RADIOTHERAPY, ADJUVANT; SALVAGE THERAPY;

EID: 77349097139     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70387-0     Document Type: Letter

References (3)

1. Chang E.L., Wefel J.S., Hess K.R., et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10 (2009) 1037-1044
2. Li J., Bentzen S.M., Renschler M., et al. Regression after whole brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. J Clin Oncol 25 (2007) 1260-1266
3. Meyers C.A., Smith J.A., Bezjak A., et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 22 (2004) 157-165